American Society of Hematology Annual Meeting & Exposition (ASH) | Conference

Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.

Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

The interview features comments on the emergence of T-cell engagers for therapy in patients with multiple myeloma made during the 2020 ASH Meeting & Exposition.

Patients with aggressive lymphomas had a sharp increase in quality of life from time of diagnosis until 1 year later.

The allogeneic off-the-shelf CD22-directed T-cell product, UCART22, showed early signs of activity and no evidence of unexpected toxicities for adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

Patients with hematologic malignancies were found to be at increased risk for significant morbidity and mortality from COVID-19, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment.

Findings from a preclinical study suggested ALVR109 could be a safe and effective treatment for the coronavirus disease 2019.

A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.